Total Payments
$2,147
2024 Payments
$61.90
Companies
36
Transactions
102
Medicare Patients
2,063
Medicare Billing
$203,442
Payment Breakdown by Category
Food & Beverage$1,742 (81.1%)
Education$404.93 (18.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,742 | 94 | 81.1% |
| Education | $404.93 | 8 | 18.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seagen Inc. | $280.79 | 6 | $0 (2023) |
| PFIZER INC. | $164.44 | 12 | $0 (2023) |
| Clovis Oncology, Inc. | $147.19 | 6 | $0 (2019) |
| Celgene Corporation | $140.23 | 6 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $137.02 | 9 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $128.65 | 3 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $115.58 | 4 | $0 (2023) |
| Astellas Pharma US Inc | $114.13 | 4 | $0 (2023) |
| EISAI INC. | $92.53 | 6 | $0 (2022) |
| Daiichi Sankyo Inc. | $79.33 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61.90 | 3 | Celgene Corporation ($25.51) |
| 2023 | $913.53 | 30 | Seagen Inc. ($261.08) |
| 2022 | $177.72 | 9 | Genentech USA, Inc. ($25.00) |
| 2021 | $39.36 | 2 | Ipsen Biopharmaceuticals, Inc ($21.64) |
| 2019 | $577.48 | 35 | PFIZER INC. ($109.78) |
| 2018 | $256.55 | 14 | Astellas Pharma US Inc ($53.77) |
| 2017 | $120.49 | 9 | Amgen Inc. ($27.83) |
All Payment Transactions
102 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: ONCOLOGY | ||||||
| 04/16/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.51 | General |
| Category: Hematology | ||||||
| 02/26/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: Oncology | ||||||
| 12/11/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Iron Deficiency Anemia | ||||||
| 11/16/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $29.31 | General |
| Category: Hematology | ||||||
| 11/10/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $29.12 | General |
| Category: Hematology | ||||||
| 11/08/2023 | Seagen Inc. | — | Education | In-kind items and services | $99.99 | General |
| 11/07/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.70 | General |
| Category: Hematology | ||||||
| 10/28/2023 | Seagen Inc. | — | Education | In-kind items and services | $99.99 | General |
| 10/27/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.66 | General |
| 10/24/2023 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: Oncology | ||||||
| 09/27/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: ONCOLOGY | ||||||
| 09/07/2023 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Oncology | ||||||
| 08/15/2023 | G1 Therapeutics, Inc. | COSELA (Drug) | Food and Beverage | Cash or cash equivalent | $19.33 | General |
| Category: ONCOLOGY | ||||||
| 08/10/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: Oncology | ||||||
| 08/07/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.07 | General |
| Category: Hematology | ||||||
| 07/26/2023 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: Oncology | ||||||
| 07/17/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: ONCOLOGY | ||||||
| 07/14/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: Oncology | ||||||
| 07/13/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $103.65 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 462 | 860 | $217,982 | $50,838 |
| 2022 | 7 | 647 | 1,177 | $298,078 | $68,706 |
| 2021 | 5 | 480 | 801 | $200,739 | $47,314 |
| 2020 | 7 | 474 | 783 | $193,005 | $36,583 |
Total Patients
2,063
Total Services
3,621
Medicare Billing
$203,442
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 97 | 237 | $74,418 | $17,298 | 23.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 212 | 388 | $82,644 | $17,244 | 20.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 90 | 172 | $36,120 | $10,697 | 29.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 28 | 28 | $11,200 | $2,843 | 25.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $7,260 | $1,571 | 21.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 20 | 20 | $6,340 | $1,186 | 18.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 323 | 596 | $126,948 | $28,586 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 131 | 311 | $97,654 | $22,911 | 23.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 91 | 167 | $35,070 | $9,347 | 26.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 35 | 35 | $16,940 | $3,414 | 20.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 38 | 38 | $12,046 | $2,117 | 17.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 15 | $6,000 | $1,602 | 26.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 15 | 15 | $3,420 | $728.04 | 21.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 198 | 349 | $69,800 | $16,490 | 23.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 72 | 180 | $54,014 | $13,229 | 24.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 73 | $23,725 | $5,801 | 24.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 67 | 74 | $15,762 | $3,980 | 25.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 35 | 35 | $15,750 | $3,405 | 21.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 35 | $10,990 | $2,799 | 25.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $5,808 | $1,202 | 20.7% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Facility | 2021 | 42 | 43 | $4,890 | $407.20 | 8.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 87 | 203 | $60,900 | $11,868 | 19.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 194 | 338 | $67,600 | $11,867 | 17.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 36 | $11,700 | $2,963 | 25.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 30 | 30 | $13,500 | $2,865 | 21.2% |
About Dr. Kumud Rangaraj, M.D
Dr. Kumud Rangaraj, M.D is a Hematology & Oncology healthcare provider based in Cumming, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649241829.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kumud Rangaraj, M.D has received a total of $2,147 in payments from pharmaceutical and medical device companies, with $61.90 received in 2024. These payments were reported across 102 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($1,742).
As a Medicare-enrolled provider, Rangaraj has provided services to 2,063 Medicare beneficiaries, totaling 3,621 services with total Medicare billing of $203,442. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Cumming, GA
- Active Since 01/27/2006
- Last Updated 11/09/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1649241829
Products in Payments
- Rubraca (Drug) $147.19
- REBLOZYL (Biological) $125.71
- KEYTRUDA (Biological) $112.41
- IBRANCE (Drug) $88.27
- INJECTAFER (Drug) $60.81
- TUKYSA (Drug) $58.66
- Lenvima (Drug) $52.64
- NINLARO (Drug) $47.63
- ADCETRIS (Biological) $46.73
- GILOTRIF (Drug) $43.61
- KRAZATI (Drug) $42.73
- Halaven (Drug) $39.89
- DARZALEX (Biological) $34.92
- Venclexta (Drug) $34.23
- VERZENIO (Drug) $33.02
- Neulasta (Biological) $29.37
- Padcev (Drug) $28.89
- Kadcyla (Biological) $25.00
- OPDIVO (Biological) $25.00
- OJJAARA (Drug) $24.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.